Advertisement
LUNG vs SRTS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LUNG is a StrongBuy and SRTS is a Hold.
LUNG in upward trend: price may jump up because it broke its lower Bollinger Band on October 06, 2026
LUNG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 33 cases where LUNG's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 58 cases where LUNG's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for LUNG just turned positive on October 20, 2026. Looking at past instances where LUNG's MACD turned positive, the stock continued to rise in 44 of 51 cases over the following month. The odds of a continued upward trend are 86%.
Following a +4.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where LUNG advanced for three days, in 214 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LUNG as a result. In 66 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
LUNG moved below its 50-day moving average on September 24, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for LUNG crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUNG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for LUNG entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.005) is normal, around the industry mean (2.923). P/E Ratio (-1.591) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.932) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. LUNG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUNG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
SRTS in downward trend: price dove below 50-day moving average on September 18, 2026
SRTS moved below its 50-day moving average on September 18, 2026 date and that indicates a change from an upward trend to a downward trend. In 33 of 39 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SRTS as a result. In 80 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The 10-day moving average for SRTS crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for SRTS entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SRTS's RSI Oscillator exited the oversold zone, 27 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRTS advanced for three days, in 232 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
SRTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.277) is normal, around the industry mean (2.923). P/E Ratio (-3.043) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (2.874) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. SRTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
LUNG | SRTS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 82 | 76 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 35 Fair valued | 29 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 39 | 74 | |
P/E GROWTH RATING 1..100 | 80 | 30 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SRTS's Valuation (29) in the Medical Specialties industry is in the same range as LUNG (35) in the null industry. This means that SRTS’s stock grew similarly to LUNG’s over the last 12 months.
SRTS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as LUNG (100) in the null industry. This means that SRTS’s stock grew similarly to LUNG’s over the last 12 months.
SRTS's SMR Rating (97) in the Medical Specialties industry is in the same range as LUNG (98) in the null industry. This means that SRTS’s stock grew similarly to LUNG’s over the last 12 months.
LUNG's Price Growth Rating (39) in the null industry is somewhat better than the same rating for SRTS (74) in the Medical Specialties industry. This means that LUNG’s stock grew somewhat faster than SRTS’s over the last 12 months.
SRTS's P/E Growth Rating (30) in the Medical Specialties industry is somewhat better than the same rating for LUNG (80) in the null industry. This means that SRTS’s stock grew somewhat faster than LUNG’s over the last 12 months.
| LUNG | SRTS | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 86% | N/A |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 79% |
| Advances ODDS (%) | 2 days ago 80% | 24 days ago 83% |
| Declines ODDS (%) | 4 days ago 84% | 3 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LUNG’s FA Score shows that 0 FA rating(s) are green while SRTS’s FA Score has 2 green FA rating(s).
- LUNG’s FA Score: 0 green, 5 red.
- SRTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LUNG’s TA Score shows that 4 TA indicator(s) are bullish while SRTS’s TA Score has 4 bullish TA indicator(s).
- LUNG’s TA Score: 4 bullish, 5 bearish.
- SRTS’s TA Score: 4 bullish, 5 bearish.
Price Growth
LUNG (@Medical/Nursing Services) experienced а +2.81% price change this week, while SRTS (@Medical/Nursing Services) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
Reported Earning Dates
LUNG is expected to report earnings on Oct 27, 2026.
SRTS is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
SRTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, SRTS has been loosely correlated with LUNG. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if SRTS jumps, then LUNG could also see price increases.
| Ticker / NAME | Correlation To SRTS | 1D Price Change % | ||
|---|---|---|---|---|
| SRTS | 100% | +4.00% | ||
| LUNG - SRTS | 57% Loosely correlated | +0.55% | ||
| HAE - SRTS | 45% Loosely correlated | -0.93% | ||
| AORT - SRTS | 35% Loosely correlated | -0.82% | ||
| GMED - SRTS | 33% Loosely correlated | -0.35% | ||
| MTD - SRTS | 28% Poorly correlated | +2.69% | ||
More | ||||